GU Cancers 2021 | ICE-PAC: avelumab with SABR in mCRPC
Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, discusses the Phase II multicenter ICE-PAC study (ACTRN12618000954224) of avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC). Dr Azad explains how SABR can be used to create a more immunogenic environment, potentially improving the efficacy of immunotherapies. The study reported an objective response rate of 31%. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Arun Azad, MBBS, PhD, FRACP, has participated in speaker bureaus with Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb, Merck Serono and Bayer, has received honoraria from Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm and Merck Sharpe Dome; has participated in scientific advisory boards with Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen and Noxopharm; has received reimbursement for travel and accommodation from Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar and Pfizer; and has received research funding from Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional) and Ipsen (institutional).
